
Key Takeaways:
- 3D Medicines competes for a share in an already hotly contested and very small market, potentially dimming its appeal to investors
- The company lost 1.46 billion yuan last year and another 290 million yuan in the first five months of this year, leaving it with only 660 million yuan in cash and cash equivalents and desperate for funds